US 12,440,466 B2
Fatty acid derivatives for treating non-alcoholic steatohepatitis
Hilde Steineger, Oslo (NO); David Alan Fraser, Blommenholm (NO); and Tore Skjæret, Oslo (NO)
Assigned to BASF AS, Oslo (NO)
Filed by BASF AS, Oslo (NO)
Filed on Jan. 22, 2024, as Appl. No. 18/418,901.
Application 18/418,901 is a continuation of application No. 16/769,659, granted, now 11,925,614, previously published as PCT/IB2018/001459, filed on Dec. 5, 2018.
Claims priority of provisional application 62/743,013, filed on Oct. 9, 2018.
Claims priority of application No. 20171944 (NO), filed on Dec. 6, 2017; and application No. 20171945 (NO), filed on Dec. 6, 2017.
Prior Publication US 2024/0156769 A1, May 16, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/202 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61P 1/16 (2006.01)
CPC A61K 31/202 (2013.01) [A61K 9/0053 (2013.01); A61K 45/06 (2013.01); A61P 1/16 (2018.01)] 17 Claims
 
1. A method of inhibiting the progression of hepatic fibrosis in a subject with non-alcoholic steatohepatitis, comprising administering to the subject a pharmaceutically effective amount of a compound of 2-(((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yl)oxy)butanoic acid (Compound A), or a pharmaceutically acceptable salt or ester thereof, having the structure:

OG Complex Work Unit Chemistry
wherein the subject has hepatic fibrosis and the hepatic fibrosis does not progress as compared to an untreated individual,
wherein the method further therapeutically treats non-alcoholic steatohepatitis.